immunoglobulin CIDP Polyneuropathy treatment
Conditions
Interventions
The investigational product is Kiovig a brand of immunoglobulin. Kiovig
will be compared to Gammagard (another brand of immunoglobulin).
The first phase is a randomised dubbel-blind phase, where pati
Sponsors
Prof. P.A. van doorn
Eligibility
Inclusion criteria
Inclusion criteria: 1. Minimum age 18 years; 2. Improvement of muscle function after start Gammagard; 3. Active illness; 4. Ongoing intermittent treatment with a stable Gammagard dose; 5. Clinical and EMG findings compatible with CIDP
Exclusion criteria
Exclusion criteria: 1. IgA deficiency or allergic reactions to IVIg; 2. Hereditary neuropathy or severe concomittant illness; 3. MMn. atypical CIDP.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. The efficacy. The ODSS will be used as the primary outcome scale. A change of more than one point will be considered as improvement or worsening. 2. The vigorimeter and MRC sumscore will be used as secondary outcome scales. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. The secondary objective will be to record the occurence of side-effects; 2. The preferences of patients regarding the medication. | — |
Contacts
Public ContactK. Kuitwaard
Erasmus MC, department Neurology, room H 673,
Outcome results
None listed